Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Methandienone** is a synthetic androgen and anabolic steroid (AAS), originally developed by CIBA in 1955, and marketed under the brand name Dianabol. It is primarily used non-medically for physique and performance enhancement, especially by bodybuilders and athletes, due to its potent anabolic properties. Methandienone functions mainly as a strong agonist of the androgen receptor, promoting enhanced protein synthesis, nitrogen retention, and glycogenolysis in muscle tissue. This leads to rapid increases in muscle mass and strength, as well as accelerated recovery. It also has moderate androgenic and estrogenic effects, including the development of male secondary sexual characteristics and estrogen-related side effects such as gynecomastia and fluid retention. Methandienone is orally active and its use may result in hepatotoxicity. Its medical use for androgen replacement therapy in conditions like hypogonadism has largely been discontinued, but it remains popular in some countries for non-medical use[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methandienone.